Company profilePharmaceutical#699 of 1,318 in Pakistan✓ No DRAP alerts

W & ALI SONS PHARMACEUTICALS

Pharmaceutical company · 14 brands · 22 molecules

14 registered products 12 pharmaceutical brands 22 distinct molecules 0 DRAP alerts

Company overview

14
registered products
12
pharmaceutical brands
22
distinct molecules
0
therapeutic classes
0
DRAP alerts

W & ALI SONS PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 14 product registrations across 22 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by W

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Top molecules by brand count

Piroxicam1 brand
Loratadine1 brand
Loratadine ...... 10 Mg1 brand
Cefixime1 brand
Ceftriaxone ...... 500 Mg1 brand
Ceftriaxone ...... 1 Gm1 brand
Ceftriaxone ...... 250 Mg1 brand
Cefotaxime ......1Gm1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official8 products · Rs 105.46 – Rs 592.75
DVAGO1 products · Rs 232.75 – Rs 232.75
Median across source: Rs 236.19

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 138 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
MEDISURE LABORATORIES PAKISTAN (PVT.) LTD. holds 74 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAmlodipineArtemetherAscorbic AcidAtorvastatin
Wilshire Laboratories (Private) Limited holds 133 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin

Get the full profile for W

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.